- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- AC-201, 25mg, AC-201, 50mg, AC-201, 75mg, Placebo
- Drug
- Lead sponsor
- TWi Biotechnology, Inc.
- Industry
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 13
- States / cities
- Chino, California • Los Angeles, California • Coral Gables, Florida + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 5,307
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Endometrial Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
- Interventions
- ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
- Genetic · Biological · Drug
- Lead sponsor
- Allogene Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 24
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more
- Conditions
- Adult Spinal Deformity, Scoliosis, Kyphosis, Sagittal Imbalance
- Interventions
- Index or spine revision surgery for complex adult spinal deformity
- Procedure
- Lead sponsor
- International Spine Study Group Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2032
- U.S. locations
- 17
- States / cities
- La Jolla, California • Sacramento, California • San Francisco, California + 11 more
- Conditions
- Obesity, Overweight
- Interventions
- LIK066, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 59
- States / cities
- Anniston, Alabama • Jasper, Alabama • Beverly Hills, California + 52 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
- Interventions
- Computed Tomography, Magnetic Resonance Imaging, Pazopanib Hydrochloride, Placebo Administration, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 579
- States / cities
- Fairbanks, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 355 more
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma
- Interventions
- Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis, Temsirolimus, Vinorelbine Tartrate
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 29 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 163
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 129 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Tislelizumab, Concurrent chemoradiotherapy (cCRT), Placebo
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Jacksonville, Florida • Winter Haven, Florida + 11 more
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD
- Interventions
- Ramelteon and Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Santa Monica, California • Miami Beach, Florida + 3 more
- Conditions
- Psoriasis
- Interventions
- Not listed
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,846 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 182
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Gadsden, Alabama + 153 more
- Conditions
- Plaque Psoriasis
- Interventions
- Deucravacitinib, Ustekinumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 3,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 122
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 101 more
- Conditions
- Hypercholesterolemia
- Interventions
- Lapaquistat acetate and stable statin therapy, Stable statin therapy
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 83 more
- Conditions
- Gout
- Interventions
- D-0120, Allopurinol
- Drug
- Lead sponsor
- InventisBio Co., Ltd
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Plantation, Florida • Evergreen Park, Illinois + 16 more
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- Inhaled Nitric Oxide, Placebo
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 5 Days to 14 Days
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Loma Linda, California • Orange, California + 26 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- inotuzumab ozogamicin, FLAG (fludarabine, cytarabine and G-CSF), HIDAC (high dose cytarabine), cytarabine and mitoxantrone
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 96
- States / cities
- La Jolla, California • Los Angeles, California • Orange, California + 39 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
- Interventions
- Ambrisentan, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more
- Conditions
- Lung Cancer
- Interventions
- immunohistochemistry staining method, biopsy, surgery
- Other · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2011
- U.S. locations
- 56
- States / cities
- Mobile, Alabama • Los Angeles, California • Pasadena, California + 37 more
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Ipilimumab, Nivolumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 201
- States / cities
- Auburn, California • Berkeley, California • Cameron Park, California + 140 more
- Conditions
- Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Clear Cell Sarcoma of the Kidney, Papillary Renal Cell Carcinoma, Rhabdoid Tumor of the Kidney, Stage I Renal Cell Cancer, Stage I Renal Wilms Tumor, Stage II Renal Cell Cancer, Stage II Renal Wilms Tumor, Stage III Renal Cell Cancer, Stage III Renal Wilms Tumor, Stage IV Renal Cell Cancer, Stage IV Renal Wilms Tumor
- Interventions
- Doxorubicin Hydrochloride, Irinotecan Hydrochloride, Conventional Surgery, Cyclophosphamide, Etoposide, Carboplatin, Dactinomycin, Vincristine Sulfate, Radiation Therapy, Laboratory Biomarker Analysis
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 161
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 127 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Interferon beta-1b (Betaferon/Betaseron, BAY86-5046), Copaxone
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 2,244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 52 more
- Conditions
- Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma
- Interventions
- Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Sunitinib Malate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 71 more
- Conditions
- Crohn's Disease
- Interventions
- placebo for risankizumab, risankizumab IV, risankizumab SC
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 931 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 117
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 94 more
- Conditions
- Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
- Interventions
- Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars), Birinapant, Venetoclax, Gemcitabine, Docetaxel, Azacitidine
- Drug
- Lead sponsor
- IGM Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Duarte, California • Los Alamitos, California + 29 more
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
- Interventions
- Cyclophosphamide, Vincristine, Dexamethasone, Inotuzumab Ozogamicin, Methotrexate, Cytarabine, Methylprednisolone, Rituximab, Prednisone, Mercaptopurine, Doxorubicin
- Drug · Biological
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Irvine, California • Orange, California + 60 more